Huntsman Ronald Kirk 4
4 · Vivos Therapeutics, Inc. · Filed Jun 3, 2022
Insider Transaction Report
Form 4
Huntsman Ronald Kirk
DirectorChief Executive Officer10% Owner
Transactions
- Purchase
Common Stock
2022-06-01$1.83/sh+4,000$7,320→ 27,500 total - Purchase
Common Stock
2022-05-31$2.03/sh+8,000$16,240→ 23,500 total
Holdings
- 1,740,000(indirect: See footnote)
Common Stock
Footnotes (2)
- [F1]The price reported in Column 4 is a weighted average price. These shares were purchased in four separate transactions ranging from $2.02 to $2.035 on May 31, 2022. The reporting person undertakes to provide to Vivos Therapeutics, Inc., any security holder of Vivos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4.
- [F2]Shares held by Coronado V Partners, LLC, of which the reporting person is a member and manager.